All clinical trials requiring authorisation by CA
A declaration of the end of a clinical trial should be sent to MHRA within 90 days of the global end of the trial.
European Standard Declaration Form (Eudralex Volume 10) to be used.
End of trial declarations shall be submitted via CESP.
"Clinical trials for medicines: manage your authorisation, report safety issues - Change your protocol, update your authorisation, report safety issues, submit safety updates and complete your end-of-trial study report"
Part 3, section 27 and Schedule 3, Part 4 of the Medicines for Human Use (Clinical Trials) Regulations 2004